The new boss of Boehringer Ingelheim
Ingelheim, July 4, 2025 – Since January 2025, Dr. Markus Wagner has been at the helm of Boehringer Ingelheim, one of the largest family-owned pharmaceutical companies worldwide. The 52-year-old biochemist, who previously served as Chief Scientific Officer at Novartis, has quickly established himself as a visionary yet pragmatic leader. But how does the new CEO tick, and what does his leadership mean for the future of the group? In an environment where the pharmaceutical industry is under pressure to innovate, Wagner is praised for his unconventional approach – and viewed critically. His plans are met with enthusiasm, but also with reservations, not least because of the political framework conditions in Germany. Wagner, born in Munich, brings an impressive resume. After studying biochemistry at LMU Munich and earning a doctorate in molecular biology, he held various leadership positions at Novartis, where he oversaw the development of several blockbuster drugs such as Entresto for heart failure…

